Regeneron Pharmaceuticals

This study tested an experimental drug called REGN5381 in people with chronic heart failure where the heart pumps less effectively. The goal was to check the drug's safety, how it behaves in the body, and its effects on a key heart stress marker. The trial was terminated early an…

This study tested if adding a new drug called CMP-001, injected directly into a tumor, could improve the effectiveness of the standard immunotherapy nivolumab for people with advanced melanoma that cannot be removed by surgery. It compared the combination treatment to nivolumab a…

This early-stage study tested a single dose of lab-made antibodies (casirivimab+imdevimab) in children hospitalized due to COVID-19. The main goals were to see how long the drug stayed in their blood and to check for safety issues. The study was terminated early and only enrolled…

This early-stage study tested whether a patient's own immune cells could be modified in a lab to recognize and attack advanced prostate cancer. The treatment, called BPX-601, involved collecting a patient's T-cells, engineering them to target a specific marker on cancer cells, an…

This early-stage study tested a new type of CAR T-cell therapy called bbT369 in adults with aggressive B-cell lymphoma that had come back or not responded to at least two prior treatments. The therapy involves modifying a patient's own immune cells to better target and fight the …

This early-stage study tested an experimental drug, REGN5093-M114, for people with advanced non-small cell lung cancer (NSCLC) whose cancer cells had high levels of a protein called MET. The main goals were to find a safe dose of the drug, both alone and combined with another med…

This study tested whether combining two immunotherapy drugs could help control several types of advanced cancer. It involved 77 people with cancers like skin cancer, lung cancer, and breast cancer. The trial was terminated early because the drug supply was discontinued, so resear…

This study tested an experimental drug called REGN4461 to see if it could help control serious metabolic problems in people with a rare genetic condition called familial partial lipodystrophy. The condition causes abnormal fat distribution and often leads to dangerously high bloo…

This study tested a new antibody combination treatment (REGN14256+imdevimab) for adults with mild COVID-19 who were otherwise healthy. The goal was to see if the treatment was safe and could help clear the virus faster and reduce symptoms. The trial was terminated early and only …

This study tested an experimental antibody drug called REGN5381 in adults whose high blood pressure remained uncontrolled despite taking one or more standard medications. The goal was to see if the new drug could safely lower blood pressure more effectively. The trial was termina…

This early-stage study tested an experimental antibody called REGN7257 in people with severe aplastic anemia, a serious bone marrow disease where the body stops making enough blood cells. The trial focused on patients whose disease did not respond to or came back after standard i…

This study tested a single shot of lab-made antibodies (casirivimab and imdevimab) to see if it could help prevent severe COVID-19 in high-risk children under 12. Researchers gave the shot to a small group of kids and tracked how long the drug stayed in their bodies and checked f…

This study tested whether regular injections of lab-made antibodies (casirivimab+imdevimab) could prevent symptomatic COVID-19 in people with weakened immune systems. It involved 66 participants who were vaccinated but had a poor antibody response or couldn't get vaccinated. The …